A biodegradable nanoadjuvant resensitizes drug-resistant Klebsiella pneumoniae to β-lactam antibiotics
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Antimicrobial agents and applications · Antibiotic Resistance in Bacteria · Orthopedic Infections and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (48)
Show source-provided references
1. Multimodal nanoimmunotherapy engages neutrophils to eliminate Staphylococcus aureus infections10.1038/s41565-024-01648-8 ↗
2. Treatment of gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair10.1186/s13054-016-1197-5 ↗
3. The characteristic of virulence, biofilm and antibiotic resistance of Klebsiella pneumoniae10.3390/ijerph17176278 ↗
4. Differential active site requirements for NDM-1 β-lactamase hydrolysis of carbapenem versus penicillin and cephalosporin antibiotics10.1038/s41467-018-06839-1 ↗
5. Structure and function relationship of OqxB efflux pump from Klebsiella pneumoniae10.1038/s41467-021-25679-0 ↗
6. Stepwise evolution of pandrug-resistance in Klebsiella pneumoniae10.1038/srep15082 ↗
7. Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control10.1080/14787210.2018.1522249 ↗
8. Phenotypic and genotypic characterization of a hypervirulent carbapenem-resistant Klebsiella pneumoniae ST17-KL38 clinical isolate harboring the carbapenemase IMP-410.1128/spectrum.02134-21 ↗
9. Cell-wall recycling of the Gram-negative bacteria and the nexus to antibiotic resistance10.1021/acs.chemrev.8b00277 ↗
10. OmpK36-mediated Carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo10.1038/s41467-019-11756-y ↗
11. Paradoxical effect of Klebsiella pneumoniae OmpK36 porin deficiency10.1080/00313020902908854 ↗
12. Efflux-mediated multiresistance in Gram-negative bacteria10.1111/j.1469-0691.2004.00763.x ↗
13. Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections10.1038/s41579-020-0420-1 ↗
14. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat10.1128/CMR.14.4.933-951.2001 ↗
15. From the regulation of peptidoglycan synthesis to bacterial growth and morphology10.1038/nrmicro2677 ↗
16. Penicillin-binding proteins and the antibacterial effectiveness of β-lactam antibiotics10.1093/clinids/8.Supplement_3.S260 ↗
17. Molecular basis of β-lactam antibiotic resistance of ESKAPE bacterium E. faecium Penicillin Binding Protein PBP510.1038/s41467-023-39966-5 ↗
18. Structure-based optimization of a non-β-lactam lead results in inhibitors that do not up-regulate β-lactamase expression in cell culture10.1021/ja042984o ↗
19. Mol · 2022
20. Interplay between β-lactamases and new β-lactamase inhibitors10.1038/s41579-019-0159-8 ↗
21. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world10.1128/AAC.00826-13 ↗
22. Antibiotic adjuvants-A strategy to unlock bacterial resistance to antibiotics10.1016/j.bmcl.2017.08.027 ↗
23. Three decades of beta-lactamase inhibitors10.1128/CMR.00037-09 ↗
24. The multiple benefits of second-generation β-lactamase inhibitors in treatment of multidrug-resistant bacteria10.1016/j.idnow.2020.11.007 ↗
25. An update on β-lactamase inhibitor discovery and development10.1016/j.drup.2017.11.002 ↗
26. Glycosylated nanotherapeutics with β-lactamase reversible competitive inhibitory activity reinvigorates antibiotics against gram-negative bacteria10.1021/acs.biomac.1c00231 ↗
27. A β-lactamase-imprinted responsive hydrogel for the treatment of antibiotic-resistant bacteria10.1002/anie.201600205 ↗
28. Phytochemical-based nanocomposites for the treatment of bacterial biofilms10.1021/acsinfecdis.9b00134 ↗
29. Maltotriose-based probes for fluorescence and photoacoustic imaging of bacterial infections10.1038/s41467-020-14985-8 ↗
30. Maltodextrin-based imaging probes detect bacteria in vivo with high sensitivity and specificity10.1038/nmat3074 ↗
31. Progressive sub-MIC exposure of Klebsiella pneumoniae 43816 to cephalothin induces the evolution of beta-lactam resistance without acquisition of beta-lactamase genes10.3390/antibiotics12050887 ↗
32. β-lactam antibiotics and β-lactamase enzymes inhibitors, part 2: our limited resources10.3390/ph15040476 ↗
33. A vehicle-free antimicrobial polymer hybrid gold nanoparticle as synergistically therapeutic platforms for Staphylococcus aureus infected wound healing10.1002/advs.202105223 ↗
34. Therapeutic nanoplatforms with bacteria-specific activation for directional transport of antibiotics10.1039/C8CC06398B ↗
35. Synthetic fluorescent nanoplatform based on benzoxaborole for broad-spectrum inhibition of bacterial adhesion to host cells10.1021/acs.chemmater.8b03346 ↗
36. Antibiotic adjuvants: make antibiotics great again10.1021/acs.jmedchem.8b01781 ↗
37. Microneedle patches with antimicrobial and immunomodulating properties for infected wound Healing10.1002/advs.202300576 ↗
38. Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function10.1038/s41598-017-10972-0 ↗
39. Interaction of N-methyl-2-alkenyl-4-quinolones with ATP-dependent MurE ligase of Mycobacterium tuberculosis: antibacterial activity, molecular docking and inhibition kinetics10.1093/jac/dkr203 ↗
40. Maltodextrin-driven MOF nano-antibacterial system for effective targeted bacteria and enhancing photodynamic therapy in bacterial keratitis10.1016/j.jconrel.2025.02.031 ↗
41. DNA nanopatch-specific modification of probiotics for ultrasound-triggered inflammatory bowel disease therapy10.1021/jacs.4c12139 ↗
42. Inhalable andrographolide-β-cyclodextrin inclusion complexes for treatment of Staphylococcus aureus pneumonia by regulating immune responses10.1021/acs.molpharmaceut.6b01162 ↗
43. Concurrent antibiosis and anti-inflammation against bacterial pneumonia by zinc hexacyanoferrate nanocatalysts10.1016/j.biomaterials.2022.121768 ↗
44. Bioinspired heteromultivalent ligand-decorated nanotherapeutic for enhanced photothermal and photodynamic therapy of antibiotic-resistant bacterial pneumonia10.1021/acsami.9b15118 ↗
45. A biomimetic non-antibiotic approach to eradicate drug-resistant infections10.1002/adma.201806024 ↗
46. Host cell polarity proteins participate in innate immunity to Pseudomonas aeruginosa infection10.1016/j.chom.2014.04.007 ↗
47. Probiotic-based nanoparticles for targeted microbiota modulation and immune restoration in bacterial pneumonia10.1093/nsr/nwac221 ↗
48. Inhibitor κBα protein therapy alleviates severe pneumonia through inhibition of nuclear factor κB10.3892/etm.2017.4130 ↗